AstraZeneca is once again teaming up with Hungarian artificial intelligence specialist Turbine as it looks to speed up and gain deeper insights into its antibody-drug conjugate discovery process.

With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs ...

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...

Antibody-drug conjugates (ADCs) embody a simple, but elegant, vision for cancer therapy—the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells—so-called smart ...

Antibody Drug Conjugates (ADCs) are a class of small molecule drugs (also known as a payload) and an antibody conjugated together by a chemical linker. ADCs are designed to target specific cells, such ...

BioNTech is putting its COVID-19 vaccine dollars to work to add a new modality to its pipeline. Sitting on $15 billion, the German biotech has doled out $170 million upfront for the rights to two ...

Dublin, April 13, 2026 (GLOBE NEWSWIRE)-- The "Antibody Drug Conjugates - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The competitive landscape report offers ...

Celltrion said on the 9th that its antibody-drug conjugate (ADC) oncology drug candidate CT-P71 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment ...